Development of Technologies that Control Scar Formation after Burn Injuries
Award amount
$1,000,000Program and phase
SBIR · Phase IIAward year
2020Award details
- Awarding agency
- Department of Defense
- Branch
- Defense Health Agency
- Recipient company
- SYNEDGEN, INC.
- Proposal award date
- 2020-03-02
- Contract end date
- 2021-07-01
- UEI
- HX79BD6YQ521
- Solicitation number
- 12.2
- Topic code
- DHP12-016
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel treatment for Crohn's disease and related inflammatory gastrointestinal disease
- Prevention and treatment of GI obstruction syndromes in cystic fibrosis
- Clinical Development of IPdR for Radiosensitization Period of Performance: 09/19/2014 - 06/18/2015
- Effective New Topical Treatment to Reduce Scar Formation in Burns
- Rectal Medication Administration Device for Palliative Care
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- KeraStat(R) Burn Gel and Halofuginone to Prevent Scar Contracture after Burn Injuries
- KeraStat(TM) Burn Gel and Halofuginone to Prevent Scar Contracture after Burn Injuries
- Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels
- Control of Scar Contracture After Burn Injury Topical Formulation
Research funding history
10 SBIR/STTR records share this UEI (2009–2020). Reported award amounts total $4,900,995. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense